Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Fractyl Health Stock Up 1.5%

Fractyl Health stock opened at $0.47 on Monday. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $3.03. The firm has a market capitalization of $64.18 million, a price-to-earnings ratio of -0.20 and a beta of 1.67. The firm has a 50-day moving average price of $1.54 and a two-hundred day moving average price of $1.37.

Institutional Trading of Fractyl Health

Several institutional investors have recently made changes to their positions in the stock. Woodline Partners LP increased its holdings in Fractyl Health by 47.2% in the first quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after buying an additional 165,786 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Fractyl Health in the second quarter worth $129,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health during the 2nd quarter worth $7,912,000. Jane Street Group LLC acquired a new position in Fractyl Health in the 2nd quarter valued at $31,000. Finally, Osaic Holdings Inc. raised its holdings in Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after acquiring an additional 49,000 shares during the period.

Analyst Ratings Changes

GUTS has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Tuesday, December 2nd. Morgan Stanley downgraded Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $8.00 to $2.00 in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Fractyl Health presently has an average rating of “Hold” and a consensus price target of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.